Kronos Bio (KRON) Q1 2025 earnings summary

Executive summary

• Discontinued lead clinical program (istisociclib) in November 2024 due to adverse events and unfavorable benefit-risk profile; initiated strategic review for alternatives including merger or dissolution.

• Entered into a Merger Agreement with Concentra Biosciences on May 1, 2025; transaction expected to close mid-2025, with a $1.4M termination fee if not completed.

• Workforce reduced by 83% as part of three restructuring plans; as of May 2025, only 8 full-time employees remain.

• All obligations under the Genentech collaboration were terminated in December 2024; all performance obligations satisfied as of March 31, 2025.

Financial highlights

• Revenue for Q1 2025 was $1.9M, down from $2.5M in Q1 2024, all from the Genentech collaboration.

• Net loss for Q1 2025 was $8.4M, a significant improvement from $30.0M in Q1 2024.

• Research and development expenses dropped to $2.1M in Q1 2025 from $14.2M in Q1 2024, reflecting program discontinuation and restructuring.

• General and administrative expenses were $6.1M in Q1 2025, down from $7.5M in Q1 2024.

• Cash, cash equivalents, and investments totaled $99.7M as of March 31, 2025.

Outlook and guidance

• Cash and investments expected to fund operations for at least 12 months from March 31, 2025.

• If the merger is not completed, the board may pursue dissolution and liquidation.

• Pending merger restricts business activities and capital allocation; significant transaction costs expected regardless of outcome.